Which factors predict cognitive decline in Parkinson's disease?
Identifieur interne : 001651 ( PubMed/Corpus ); précédent : 001650; suivant : 001652Which factors predict cognitive decline in Parkinson's disease?
Auteurs : D. Caparros-Lefebvre ; N. Pécheux ; V. Petit ; A. Duhamel ; H. PetitSource :
- Journal of neurology, neurosurgery, and psychiatry [ 0022-3050 ] ; 1995.
English descriptors
- KwdEn :
- Activities of Daily Living, Age of Onset, Aged, Cognition Disorders (diagnosis), Cognition Disorders (etiology), Depressive Disorder (etiology), Depressive Disorder (psychology), Educational Status, Humans, Levodopa (therapeutic use), Middle Aged, Movement Disorders (etiology), Neuropsychological Tests, Parkinson Disease (complications), Parkinson Disease (drug therapy), Prognosis, Severity of Illness Index, Task Performance and Analysis, Tremor (etiology).
- MESH :
- chemical , therapeutic use : Levodopa.
- complications : Parkinson Disease.
- diagnosis : Cognition Disorders.
- drug therapy : Parkinson Disease.
- etiology : Cognition Disorders, Depressive Disorder, Movement Disorders, Tremor.
- psychology : Depressive Disorder.
- Activities of Daily Living, Age of Onset, Aged, Educational Status, Humans, Middle Aged, Neuropsychological Tests, Prognosis, Severity of Illness Index, Task Performance and Analysis.
Abstract
The study assessed cognitive decline in non-demented, non-depressed patients with well defined Parkinson's disease and determined the predictive value for cognitive decline of different motor symptoms. Motor disability was measured with the Unified Parkinson's disease rating scale, impairment in activities of daily living, levodopa test, and long term clinical follow up. Neuropsychological evaluations included modified mini mental state, fluency, Wechsler logical memory, Wisconsin card sorting test, and the Montgomery and Asberg depression rating scale. Fifty three patients fulfilling clinical criteria for idiopathic Parkinson's disease were studied. Cognitive performance on initial testing was significantly correlated with education and disease duration but not with age at disease onset. Cognitive performance on retesting after three years of follow up was significantly reduced. This reduction was significantly greater in the late onset group, in patients with isolated dystonic dyskinesiae, and in patients with a lower percentage of motor improvement on levodopa. Cognitive decline in idiopathic Parkinson's disease may depend on both the prevalence of non-dopaminergic lesions and the topography of dopaminergic denervation. Predictive factors for cognitive decline, especially in executive tasks, relate more to non-dopaminergic than to dopaminergic lesions.
PubMed: 7823067
Links to Exploration step
pubmed:7823067Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Which factors predict cognitive decline in Parkinson's disease?</title><author><name sortKey="Caparros Lefebvre, D" sort="Caparros Lefebvre, D" uniqKey="Caparros Lefebvre D" first="D" last="Caparros-Lefebvre">D. Caparros-Lefebvre</name><affiliation><nlm:affiliation>Department of Neurology, CHU Lille, France.</nlm:affiliation></affiliation></author><author><name sortKey="Pecheux, N" sort="Pecheux, N" uniqKey="Pecheux N" first="N" last="Pécheux">N. Pécheux</name></author><author><name sortKey="Petit, V" sort="Petit, V" uniqKey="Petit V" first="V" last="Petit">V. Petit</name></author><author><name sortKey="Duhamel, A" sort="Duhamel, A" uniqKey="Duhamel A" first="A" last="Duhamel">A. Duhamel</name></author><author><name sortKey="Petit, H" sort="Petit, H" uniqKey="Petit H" first="H" last="Petit">H. Petit</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1995">1995</date><idno type="RBID">pubmed:7823067</idno><idno type="pmid">7823067</idno><idno type="wicri:Area/PubMed/Corpus">001651</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001651</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Which factors predict cognitive decline in Parkinson's disease?</title><author><name sortKey="Caparros Lefebvre, D" sort="Caparros Lefebvre, D" uniqKey="Caparros Lefebvre D" first="D" last="Caparros-Lefebvre">D. Caparros-Lefebvre</name><affiliation><nlm:affiliation>Department of Neurology, CHU Lille, France.</nlm:affiliation></affiliation></author><author><name sortKey="Pecheux, N" sort="Pecheux, N" uniqKey="Pecheux N" first="N" last="Pécheux">N. Pécheux</name></author><author><name sortKey="Petit, V" sort="Petit, V" uniqKey="Petit V" first="V" last="Petit">V. Petit</name></author><author><name sortKey="Duhamel, A" sort="Duhamel, A" uniqKey="Duhamel A" first="A" last="Duhamel">A. Duhamel</name></author><author><name sortKey="Petit, H" sort="Petit, H" uniqKey="Petit H" first="H" last="Petit">H. Petit</name></author></analytic><series><title level="j">Journal of neurology, neurosurgery, and psychiatry</title><idno type="ISSN">0022-3050</idno><imprint><date when="1995" type="published">1995</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Activities of Daily Living</term><term>Age of Onset</term><term>Aged</term><term>Cognition Disorders (diagnosis)</term><term>Cognition Disorders (etiology)</term><term>Depressive Disorder (etiology)</term><term>Depressive Disorder (psychology)</term><term>Educational Status</term><term>Humans</term><term>Levodopa (therapeutic use)</term><term>Middle Aged</term><term>Movement Disorders (etiology)</term><term>Neuropsychological Tests</term><term>Parkinson Disease (complications)</term><term>Parkinson Disease (drug therapy)</term><term>Prognosis</term><term>Severity of Illness Index</term><term>Task Performance and Analysis</term><term>Tremor (etiology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Cognition Disorders</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Cognition Disorders</term><term>Depressive Disorder</term><term>Movement Disorders</term><term>Tremor</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Depressive Disorder</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Activities of Daily Living</term><term>Age of Onset</term><term>Aged</term><term>Educational Status</term><term>Humans</term><term>Middle Aged</term><term>Neuropsychological Tests</term><term>Prognosis</term><term>Severity of Illness Index</term><term>Task Performance and Analysis</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The study assessed cognitive decline in non-demented, non-depressed patients with well defined Parkinson's disease and determined the predictive value for cognitive decline of different motor symptoms. Motor disability was measured with the Unified Parkinson's disease rating scale, impairment in activities of daily living, levodopa test, and long term clinical follow up. Neuropsychological evaluations included modified mini mental state, fluency, Wechsler logical memory, Wisconsin card sorting test, and the Montgomery and Asberg depression rating scale. Fifty three patients fulfilling clinical criteria for idiopathic Parkinson's disease were studied. Cognitive performance on initial testing was significantly correlated with education and disease duration but not with age at disease onset. Cognitive performance on retesting after three years of follow up was significantly reduced. This reduction was significantly greater in the late onset group, in patients with isolated dystonic dyskinesiae, and in patients with a lower percentage of motor improvement on levodopa. Cognitive decline in idiopathic Parkinson's disease may depend on both the prevalence of non-dopaminergic lesions and the topography of dopaminergic denervation. Predictive factors for cognitive decline, especially in executive tasks, relate more to non-dopaminergic than to dopaminergic lesions.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">7823067</PMID><DateCreated><Year>1995</Year><Month>02</Month><Day>14</Day></DateCreated><DateCompleted><Year>1995</Year><Month>02</Month><Day>14</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-3050</ISSN><JournalIssue CitedMedium="Print"><Volume>58</Volume><Issue>1</Issue><PubDate><Year>1995</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Journal of neurology, neurosurgery, and psychiatry</Title><ISOAbbreviation>J. Neurol. Neurosurg. Psychiatr.</ISOAbbreviation></Journal><ArticleTitle>Which factors predict cognitive decline in Parkinson's disease?</ArticleTitle><Pagination><MedlinePgn>51-5</MedlinePgn></Pagination><Abstract><AbstractText>The study assessed cognitive decline in non-demented, non-depressed patients with well defined Parkinson's disease and determined the predictive value for cognitive decline of different motor symptoms. Motor disability was measured with the Unified Parkinson's disease rating scale, impairment in activities of daily living, levodopa test, and long term clinical follow up. Neuropsychological evaluations included modified mini mental state, fluency, Wechsler logical memory, Wisconsin card sorting test, and the Montgomery and Asberg depression rating scale. Fifty three patients fulfilling clinical criteria for idiopathic Parkinson's disease were studied. Cognitive performance on initial testing was significantly correlated with education and disease duration but not with age at disease onset. Cognitive performance on retesting after three years of follow up was significantly reduced. This reduction was significantly greater in the late onset group, in patients with isolated dystonic dyskinesiae, and in patients with a lower percentage of motor improvement on levodopa. Cognitive decline in idiopathic Parkinson's disease may depend on both the prevalence of non-dopaminergic lesions and the topography of dopaminergic denervation. Predictive factors for cognitive decline, especially in executive tasks, relate more to non-dopaminergic than to dopaminergic lesions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Caparros-Lefebvre</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology, CHU Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pécheux</LastName><ForeName>N</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Petit</LastName><ForeName>V</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Duhamel</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Petit</LastName><ForeName>H</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neurol Neurosurg Psychiatry</MedlineTA><NlmUniqueID>2985191R</NlmUniqueID><ISSNLinking>0022-3050</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Adv Neurol. 1987;45:383-92</RefSource><PMID Version="1">2881447</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Rev Neurol (Paris). 1985;141(5):413-5</RefSource><PMID Version="1">4048732</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Adv Neurol. 1987;45:409-11</RefSource><PMID Version="1">3825717</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Adv Neurol. 1987;45:413-6</RefSource><PMID Version="1">3825718</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 1988 Feb;51(2):244-9</RefSource><PMID Version="1">3346689</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain. 1988 Jun;111 ( Pt 3):525-39</RefSource><PMID Version="1">3382911</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 1989 Feb;52(2):201-6</RefSource><PMID Version="1">2703838</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 1989;4 Suppl 1:S95-119</RefSource><PMID Version="1">2657411</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 1989 Jun;39(6):762-8</RefSource><PMID Version="1">2725868</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 1989 Sep;26(3):309-20</RefSource><PMID Version="1">2802531</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 1990 Jan;40(1):38-41</RefSource><PMID Version="1">2296380</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trends Neurosci. 1990 Jan;13(1):21-9</RefSource><PMID Version="1">1688671</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain. 1991 Oct;114 ( Pt 5):2095-122</RefSource><PMID Version="1">1933236</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 1993 May;33(5):445-50</RefSource><PMID Version="1">8498822</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 1994 Jan;9(1):2-12</RefSource><PMID Version="1">8139601</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cortex. 1976 Dec;12(4):313-24</RefSource><PMID Version="1">1009768</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Rev Neurol (Paris). 1977 Aug-Sep;133(8-9):445-54</RefSource><PMID Version="1">929037</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Neurol. 1978 May;35(5):261-3</RefSource><PMID Version="1">646679</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Psychiatry. 1979 Apr;134:382-9</RefSource><PMID Version="1">444788</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 1981 Jun;31(6):645-50</RefSource><PMID Version="1">7195481</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 1982 Feb;32(2):133-7</RefSource><PMID Version="1">7198740</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Adv Neurol. 1984;40:229-34</RefSource><PMID Version="1">6695599</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 1985 Jan 5;1(8419):43-4</RefSource><PMID Version="1">2856962</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Adv Neurol. 1987;45:405-8</RefSource><PMID Version="1">3825716</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 1992 Mar;55(3):181-4</RefSource><PMID Version="1">1564476</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 1992 Apr;42(4 Suppl 5):141-3</RefSource><PMID Version="1">1574170</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Rev Neurol (Paris). 1992;148(2):117-22</RefSource><PMID Version="1">1604121</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 1993 Mar;56(3):268-73</RefSource><PMID Version="1">8459243</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000203" MajorTopicYN="N">Activities of Daily Living</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004522" MajorTopicYN="N">Educational Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007980" MajorTopicYN="N">Levodopa</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009069" MajorTopicYN="N">Movement Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013647" MajorTopicYN="N">Task Performance and Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014202" MajorTopicYN="N">Tremor</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading></MeshHeadingList><OtherID Source="NLM">PMC1073268</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1995</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1995</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1995</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">7823067</ArticleId><ArticleId IdType="pmc">PMC1073268</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001651 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001651 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:7823067
|texte= Which factors predict cognitive decline in Parkinson's disease?
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:7823067" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |